1244 — 3D Medicines Share Price
Last trade - 00:00- HK$1.44bn
- HK$591.51m
- CNY634.95m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.42 | ||
| Price to Tang. Book | 1.42 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.09 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -59.74% | ||
| Return on Equity | -55.83% | ||
| Operating Margin | -87.36% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | n/a | 60.26 | 567.39 | 634.95 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
3D Medicines Inc is a China-based holding company mainly engaged in the research and development (R&D) and commercialization of biopharmaceuticals. The Company focuses on the discovery, development and commercialization of innovative drugs in the field of cancer chronic disease treatment, and also lays out the field of cancer pain management. The Company has built a complete set of internal R&D systems, and has covered the entire process from drug discovery, preclinical development, clinical trials, and registration. The Company's first marketed drug, Envafolimab, is a subcutaneously injected PD-L1 inhibitor for the treatment of pan-tumor types. The Company also has a number of innovative drug research and development pipelines. The Company primarily operates in the domestic Chinese market.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 30th, 2022
- Public Since
- December 15th, 2022
- No. of Employees
- 198
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 258,207,000
- Address
- SHANGHAI
- Web
- https://www.3d-medicines.com/
- Phone
- Auditors
- Ernst & Young
Similar to 1244
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
Guangzhou Baiyunshan Pharmaceutical Holdings Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:00 UTC, shares in 3D Medicines are trading at HK$5.56. This share price information is delayed by 15 minutes.
Shares in 3D Medicines last closed at HK$5.56 and the price had moved by -91.98% over the past 365 days. In terms of relative price strength the 3D Medicines share price has underperformed the FTSE Developed Asia Pacific Index by -91.63% over the past year.
There is no consensus recommendation for this security.
3D Medicines does not currently pay a dividend.
3D Medicines does not currently pay a dividend.
3D Medicines does not currently pay a dividend.
To buy shares in 3D Medicines you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$5.56, shares in 3D Medicines had a market capitalisation of HK$1.44bn.
Here are the trading details for 3D Medicines:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1244
Based on an overall assessment of its quality, value and momentum 3D Medicines is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 3D Medicines. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -40.66%.
As of the last closing price of HK$5.56, shares in 3D Medicines were trading -74.06% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The 3D Medicines PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$5.56.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on 3D Medicines' directors